Literature DB >> 24757113

Psychiatric issues in cognitive impairment.

Dag Aarsland1, John-Paul Taylor, Daniel Weintraub.   

Abstract

Neuropsychiatric symptoms (NPS) such as depression, hallucinations and apathy commonly occur in Parkinson's disease (PD) and have major clinical consequences including a negative impact on quality of life. This review discusses the epidemiology, clinical features, diagnostic procedures and treatment issues of NPS in PD and related disorders in the perspective of cognitive impairment, focusing on depression, anxiety, visual hallucinations, apathy, sleep disturbances, impulse control disorder and non-motor fluctuations. The majority of NPS are more common in PD patients with dementia, possibly related to shared underlying pathologies. Recent studies also suggest that NPS are associated with mild cognitive impairment in PD, in particular with the amnestic type. Accurate diagnosis of NPS is important but can be difficult, due to overlapping symptoms and similar appearance of symptoms of motor symptoms of parkinsonism, cognitive impairment, mood disorders and apathy. There are few systematic studies focusing on the management of NPS in PD with cognitive impairment.
© 2014 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  Neuropsychiatric symptoms, Parkinson's disease, cognitive impairment, depression, psychosis, anxiety, apathy

Mesh:

Year:  2014        PMID: 24757113      PMCID: PMC4380016          DOI: 10.1002/mds.25873

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  165 in total

1.  Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial.

Authors:  Dan A Mendonça; Krishe Menezes; Mandar S Jog
Journal:  Mov Disord       Date:  2007-10-31       Impact factor: 10.338

2.  Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease. A randomized, double blind, placebo-controlled study.

Authors:  Camila Andrade Mendes Medeiros; Pedro Felipe Carvalhedo de Bruin; Lívia Ariane Lopes; Maria Cecília Magalhães; Maria de Lourdes Seabra; Veralice Meireles Sales de Bruin
Journal:  J Neurol       Date:  2007-04-03       Impact factor: 4.849

3.  Why people see things that are not there: a novel Perception and Attention Deficit model for recurrent complex visual hallucinations.

Authors:  Daniel Collerton; Elaine Perry; Ian McKeith
Journal:  Behav Brain Sci       Date:  2005-12       Impact factor: 12.579

4.  Psychosocial factors in Parkinson's disease.

Authors:  B MacCarthy; R Brown
Journal:  Br J Clin Psychol       Date:  1989-02

5.  Fluctuations in cognition and alertness vary independently in dementia with Lewy bodies.

Authors:  Donald L Bliwise; Michael K Scullin; Lynn Marie Trotti
Journal:  Mov Disord       Date:  2013-10-22       Impact factor: 10.338

6.  A single-center, cross-sectional prevalence study of impulse control disorders in Parkinson disease: association with dopaminergic drugs.

Authors:  Michele Poletti; Chiara Logi; Claudio Lucetti; Paolo Del Dotto; Filippo Baldacci; Andrea Vergallo; Martina Ulivi; Simone Del Sarto; Giuseppe Rossi; Roberto Ceravolo; Ubaldo Bonuccelli
Journal:  J Clin Psychopharmacol       Date:  2013-10       Impact factor: 3.153

7.  Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson's disease.

Authors:  Claudio Pacchetti; Raffaele Manni; Roberta Zangaglia; Francesca Mancini; Enrico Marchioni; Cristina Tassorelli; Michele Terzaghi; Maria Ossola; Emilia Martignoni; Arrigo Moglia; Giuseppe Nappi
Journal:  Mov Disord       Date:  2005-11       Impact factor: 10.338

8.  A 12-year population-based study of psychosis in Parkinson disease.

Authors:  Elin B Forsaa; Jan Petter Larsen; Tore Wentzel-Larsen; Christopher G Goetz; Glenn T Stebbins; Dag Aarsland; Guido Alves
Journal:  Arch Neurol       Date:  2010-08

9.  Nocturnal sleep enhances working memory training in Parkinson's disease but not Lewy body dementia.

Authors:  Michael K Scullin; Lynn Marie Trotti; Anthony G Wilson; Sophia A Greer; Donald L Bliwise
Journal:  Brain       Date:  2012-08-20       Impact factor: 13.501

10.  Hallucinations in Parkinson's disease: a follow-up study.

Authors:  Anne Doé de Maindreville; Gilles Fénelon; Florence Mahieux
Journal:  Mov Disord       Date:  2005-02       Impact factor: 10.338

View more
  16 in total

Review 1.  The Therapeutic Potential of Exercise to Improve Mood, Cognition, and Sleep in Parkinson's Disease.

Authors:  Gretchen O Reynolds; Michael W Otto; Terry D Ellis; Alice Cronin-Golomb
Journal:  Mov Disord       Date:  2015-12-30       Impact factor: 10.338

2.  Introduction: the importance of cognition in movement disorders.

Authors:  David Burn; Daniel Weintraub; Trevor Robbins
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

3.  Cross-Cultural Differences of the Non-Motor Symptoms Studied by the Traditional Chinese Version of the International Parkinson and Movement Disorder Society- Unified Parkinson's Disease Rating Scale.

Authors:  Rwei-Ling Yu; Ruey-Meei Wu; Anne Y Y Chan; Vincent Mok; Yih-Ru Wu; Barbara C Tilley; Sheng Luo; Lu Wang; Nancy R LaPelle; Glenn T Stebbins; Christopher G Goetz
Journal:  Mov Disord Clin Pract       Date:  2016-04-08

4.  Neuropsychiatric Symptoms and Functional Connectivity in Mild Cognitive Impairment.

Authors:  Catherine E Munro; Nancy J Donovan; Brendan J Guercio; Sarah E Wigman; Aaron P Schultz; Rebecca E Amariglio; Dorene M Rentz; Keith A Johnson; Reisa A Sperling; Gad A Marshall
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

5.  Cognitive phenotypes in parkinson's disease differ in terms of brain-network organization and connectivity.

Authors:  Renaud Lopes; Christine Delmaire; Luc Defebvre; Anja J Moonen; Annelien A Duits; Paul Hofman; Albert F G Leentjens; Kathy Dujardin
Journal:  Hum Brain Mapp       Date:  2016-11-17       Impact factor: 5.038

6.  Genetic reduction of mitochondrial complex I function does not lead to loss of dopamine neurons in vivo.

Authors:  Hyung-Wook Kim; Won-Seok Choi; Noah Sorscher; Hyung Joon Park; François Tronche; Richard D Palmiter; Zhengui Xia
Journal:  Neurobiol Aging       Date:  2015-05-16       Impact factor: 4.673

7.  Succinobucol, a Non-Statin Hypocholesterolemic Drug, Prevents Premotor Symptoms and Nigrostriatal Neurodegeneration in an Experimental Model of Parkinson's Disease.

Authors:  Danúbia Bonfanti Santos; Dirleise Colle; Eduardo Luiz Gasnhar Moreira; Mariana Appel Hort; Marcelo Godoi; Gael Le Douaron; Antonio Luiz Braga; Jamil Assreuy; Patrick Pierre Michel; Rui Daniel Prediger; Rita Raisman-Vozari; Marcelo Farina
Journal:  Mol Neurobiol       Date:  2016-02-06       Impact factor: 5.590

Review 8.  Laboratory assessments in the course of Parkinson's disease: a clinician's perspective.

Authors:  Thomas Müller; Horst Baas; Jan Kassubek; Peter Riederer; Peter Paul Urban; Christoph Schrader; Heinz Reichmann; Dirk Woitalla; Manfred Gerlach
Journal:  J Neural Transm (Vienna)       Date:  2015-11-14       Impact factor: 3.575

Review 9.  Psychosis in Parkinson's Disease: Epidemiology, Pathophysiology, and Management.

Authors:  Anna Chang; Susan H Fox
Journal:  Drugs       Date:  2016-07       Impact factor: 9.546

10.  Chronic deep brain stimulation of the medial forebrain bundle reverses depressive-like behavior in a hemiparkinsonian rodent model.

Authors:  Luciano L Furlanetti; Volker A Coenen; Iñigo A Aranda; Máté D Döbrössy
Journal:  Exp Brain Res       Date:  2015-07-21       Impact factor: 1.972

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.